First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...
Objective: To investigate risk factors for postoperative incisional infection after spinal tumor surgery, develop a risk ...
Hepcidin and ferritin-based indices help identify patients with active inflammatory bowel disease who are less likely to respond to iron therapy.
Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...
InvestorsHub on MSN
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
Stock drops after development setback Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company ...
Agios Pharmaceuticals said on Tuesday it is discontinuing development of its sickle cell disease treatment after trial ...
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment, sending its shares down 14% in premarket trading. The trial was designed to characterize the ...
The U.S. Food and Drug Administration is speeding up its review of an oral medicine for sickle cell disease that may fill a ...
A laser-based innovation could allow electron microscopes to reveal biological structures that have long remained beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results